Potential Mechanisms and Effects of Chinese Medicines in Treatment of Diabetic Atherosclerosis by Modulating NLRP3 Inflammasome: A Narrative Review

Jia-yao YUAN; Yu FU; Zhi-hai FENG; Feng SANG; Ming-yi SHAO; Lei-lei LI

doi:10.1007/s11655-022-3513-4

Your Location：

Home >

Browse articles >

Potential Mechanisms and Effects of Chinese Medicines in Treatment of Diabetic Atherosclerosis by Modulating NLRP3 Inflammasome: A Narrative Review

Review | Updated：2022-07-20

- Potential Mechanisms and Effects of Chinese Medicines in Treatment of Diabetic Atherosclerosis by Modulating NLRP3 Inflammasome: A Narrative Review
- Chinese Journal of Integrative Medicine Vol. 28, Issue 8, Pages: 753-761(2022)
- Affiliations：
  
  1.School of First Clinical, Henan University of Chinese Medicine,Zhengzhou (450000), China
  2.Department of Endocrinology,The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou (450000), China
  3.Department of Key Laboratory of Viral Diseases Prevention and Treatment of Traditional Chinese Medicine of Henan Province, The First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou (450000), China
  4.Department of Gastroenterology,The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou (450000), China
- Author bio：
  
  Dr. FU Yu, E-mail: kybfuyu@126.com
- Funds：
- DOI：10.1007/s11655-022-3513-4
  CLC：
- Published：2022-08，
  
  Published Online：04 May 2022，
  
  Accepted：31 October 2021
Scan for full text
Jia-yao YUAN, Yu FU, Zhi-hai FENG, et al. Potential Mechanisms and Effects of Chinese Medicines in Treatment of Diabetic Atherosclerosis by Modulating NLRP3 Inflammasome: A Narrative Review. [J]. Chinese Journal of Integrative Medicine 28(8):753-761(2022)
DOI：

Jia-yao YUAN, Yu FU, Zhi-hai FENG, et al. Potential Mechanisms and Effects of Chinese Medicines in Treatment of Diabetic Atherosclerosis by Modulating NLRP3 Inflammasome: A Narrative Review. [J]. Chinese Journal of Integrative Medicine 28(8):753-761(2022) DOI： 10.1007/s11655-022-3513-4.

摘要

核苷酸结合寡聚化结构域样受体3 (NLRP3) 是一种能识别内源性危险信号和外源性刺激物并诱导NLRP3炎症小体组装的胞内感受蛋白. NLRP3炎症小体的激活能够诱导促炎因子白介素 (IL) -1β、IL-18的表达和细胞焦亡. 研究显示

NLRP3炎症小体能够通过胰岛β细胞功能障碍

胰岛素抵抗

血管内皮细胞损伤、单核细胞黏附和浸润

平滑肌细胞增殖和迁移等病理机制

参与糖尿病动脉粥样硬化的发生和发展. 已经有研究显示

中医药能够调控NLRP3炎性小体介导的炎症反应从而改善糖尿病动脉粥样硬化. 本文就NLRP3炎症小体在糖尿病动脉粥样硬化发病机制和中医药治疗中的最新进展进行综述.

Abstract

Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) is an intracellular sensor that detects endogenous danger signals and environmental irritants to assemble into the NLRP3 inflammasome. Activation of the NLRP3 inflammasome leads to the secretion of the proinflammatory cytokines interleutkin (IL)-1β and IL-18 and induces pyroptosis. Recent studies have shown that the NLRP3 inflammasome participates in the initiation and progression of diabetic atherosclerosis through pathological mechanisms such as β-cell dysfunction

insulin resistance

endothelial cell dysfunction

monocyte adhesion and infiltration

and smooth muscle cell proliferation and migration. In diabetic atherosclerosis

Chinese medicine has been proven effective for the inflammatory response mediated by the NLRP3 inflammasome. This review summarizes the latest progress on the NLRP3 inflammasome in the pathogenesis and potential Chinese medicine treatment of diabetic atherosclerosis.

关键词

中医药糖尿病动脉粥样硬化核苷酸结合寡聚化结构域样受体3 (NLRP3) 炎症小体白介素 (IL) -1β硫氧还蛋白结合蛋白 (TXNIP)细胞焦亡

Keywords

Chinese medicinediabetic atherosclerosisNLRP3 inflammasomeinterleukin-1βTXNIPpyroptosis

references

IDF Diabetes Atlas. 9th ed. Brussels, Belgium: 2019. Available at: https://www.diabetesatlas.orghttps://www.diabetesatlas.org.

Hasheminasabgorji E, Jha JC. Dyslipidemia, diabetes and atherosclerosis: role of inflammation and ROS-Redox-sensitive factors. Biomedicines 2021;9:1602.

Tian JF, Liu YF, Liu Y, et al. Cellular and molecular mechanisms of diabetic atherosclerosis: herbal medicines as a potential therapeutic approach. Oxid Med Cell Longev 2017;2017:9080869.

Lee HM, Kim JJ, Kim HJ, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes.Diabetes 2013;62:194-204.

Sharma BR, Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol 2021;22:550-559.

Gong T, Liu L, Jiang W, et al. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 2020;20:95-112.

Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome:molecular activation and regulation to therapeutics. Nat Rev Immunol 2019;19:477-489.

Shi JJ, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death.Nature 2015;526:660-665.

Rathinam VAK, Zhao Y, Shao F. Innate immunity to intracellular LPS. Nat Immunol 2019;20:527-533.

Rao Z, Chen X, Wu J, et al. Vitamin D receptor inhibits NLRP3 activation by impeding its BRCC3-mediated deubiquitination. Front Immunol 2019;10:2783.

Song N, Liu ZS, Xue W, et al. NLRP3 phosphorylation is an essential priming event for inflammasome activation. Mol Cell 2017;68:185-197.

Di A, Xiong S, Ye Z, et al. The TWIK2 potassium efflux channel in macrophages mediates NLRP3 inflammasome-induced inflammation. Immunity 2018;49:56-65.

Yang Y, Wang H, Kouadir M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis 2019;10:128.

Lauterbach MA, Saavedra V, Mangan MSJ, et al.1-Deoxysphingolipids cause autophagosome and lysosome accumulation and trigger NLRP3 inflammasome activation.Autophagy 2021;17:1947-1961.

Santos JC, Boucher D, Schneider LK, et al. Human GBP1 binds LPS to initiate assembly of a caspase-4 activating platform on cytosolic bacteria. Nat Commun 2020;11:3276.

Gaidt MM, Ebert TS, Chauhan D, et al. Human monocytes engage an alternative inflammasome pathway. Immunity 2016;44:833-846.

Gaidt MM, Hornung V. Alternative inflammasome activation enables IL-1β release from living cells. Curr Opin Immunol 2017;44:7-13.

Li D, Yang SJ, Xing YW, et al. Novel insights and current evidence for mechanisms of atherosclerosis: mitochondrial dynamics as a potential therapeutic target. Front Cell Dev Biol 2021;9:673839.

Han Y, Xu X, Tang C, et al. Reactive oxygen species promote tubular injury in diabetic nephropathy: the role of the mitochondrial ROS-TXNIP-NLRP3 biological axis.Redox Biol 2018;16:32-46.

Wan ZF, Fan Y, Liu XJ, et al. NLRP3 inflammasome promotes diabetes-induced endothelial inflammation and atherosclerosis.Diabetes Metab Syndr Obes 2019;12:1931-1942.

Pi XC, Xie L, Patterson C. Emerging roles of vascular endothelium in metabolic homeostasis. Circ Res 2018;123:477-494.

Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of cantos and beyond. J Am Coll Cardiol 2017;70:2278-2289.

Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003;23:656-660.

Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-1131.

Evavold CL, Ruan JB, Tan YH, et al. The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages. Immunity 2018;48:35-44.

Liu P, Zhang Z, Wang J, et al. Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3/caspase-1/GSDMD pathway in pancreatic β cells: in vitro and in vivo studies.Bioengineered 2021;12:9356-9366.

Yin Y, Li XY, Sha XJ, et al. Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway.Arterioscler Thromb Vasc Biol 2015;35:804-816.

Han Y, Qiu H, Pei X, et al. Low-dose sinapic acid abates the pyroptosis of macrophages by downregulation of lncRNA-MALAT1 in rats with diabetic atherosclerosis. J Cardiovasc Pharmacol 2018;71:104-112.

Abbate A, Toldo S, Marchetti C, et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res 2020;126:1260-1280.

Corcoran SE, Halai R, Cooper MA. Pharmacological inhibition of the Nod-like receptor family pyrin domain containing 3 inflammasome with MCC950. Pharmacol Rev 2021;73:968-1000.

Bäck M, Yurdagul A Jr, Tabas I, et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol 2019;16:389-406.

Zhang SJ, Li ZH, Zhang YD, et al. Ketone body 3-hydroxybutyrate ameliorates atherosclerosis via receptor GPR109α-mediated calcium influx. Adv Sci (Weinh)2021;8:2003410.

Eckel RH, Bornfeldt KE, Goldberg IJ. Cardiovascular disease in diabetes, beyond glucose. Cell Metab 2021;33:1519-1545.

Tong XL, Liu XM, Wei JP, et al. Guideline for prevention and treatment of diabetes in Chinese medicine. Chin Med Modern Dist Edu China (Chin) 2011;9:148-151.

Fu HM, Ren QY, Chang B. Mechanism of Didang Decoction in inhibiting aortic NLRP3 inflammasome cascade of mice with diabetic macrovascular disease. Chin J Exp Tradit Med Formula (Chin) 2021;27:1-8.

Xu LT, Yu HH, Xu T, et al. Mechanism of Huanglian Jiedu Decoction in regulating NLRP3 inflammasome to improve atherosclerosis. Chin J Immunol (Chin) 2020;36:815-820.

Li QF, Wang WK, Gong M, et al. Danggui Buxue Decoction and its active ingredients regulate atherosclerosis and network pharmacology in diabetic rats through the NLRP3/ASC/caspase-1 pathway. Chin Tradit Patent Med (Chin)2021;8:1-9.

Ju JQ. Mechanism of Qingxin Jieyu Formula in regulating macrophage pyroptosis and stable atherosclerosis vulnerable plaques (Dissertation). Beijing: Beijing University of Chinese Medicine; 2019.

Liu MN, Yang SJ, Luo G, et al. Research on molecular mechanism of Zhilong Huoxue Tongyu Capsule on anti-atherosclerosis based on NLRP3 inflammasome signaling pathway. Pharmacol Clin Chin Mater Med (Chin)2020;36:184-190.

Ge F, Wang WK, Zhu JT, et al. Astragaloside Ⅳ regulates blood lipid and inflammatory factors through NLRP3 inflammasome in early diabetic atherosclerosis rats. J Nanjing Univ Tradit Chin Med (Chin) 2021;37:383-387.

Qian WB, Cai XR, Qian QH, et al. Astragaloside Ⅳ protects endothelial progenitor cells from the damage of ox-LDL via the LOX-1/NLRP3 inflammasome pathway. Drug Des Devel Ther 2019;13:2579-2589.

Leng B, Zhang YJ, Liu XR, et al. Astragaloside Ⅳsuppresses high glucose-induced NLRP3 inflammasome activation by inhibiting TLR4/NF-B and CaSR. Mediat Inflamm 2019;2019:1082497.

Zhao Y, Li Q, Zhao WJ, et al. Astragaloside Ⅳ and cycloastragenol are equally effective in inhibition of endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation in the endothelium. J Ethnopharmacol 2015;169:210-218.

Lian DW, Yuan HQ, Yin XZ, et al. Puerarin inhibits hyperglycemia-induced inter-endothelial junction through suppressing endothelial NLRP3 inflammasome activation via ROS-dependent oxidative pathway. Phytomedicine 2019;55:310-319.

Lian DW, Liu JY, Han RF, et al. Kakonein restores diabetes-induced endothelial junction dysfunction via promoting autophagy-mediated NLRP3 inflammasome degradation. J Cell Mol Med 2021;25:7169-7180.

Wang W, Wu QH, Sui Y, et al. Rutin protects endothelial dysfunction by disturbing Nox4 and ROS-sensitive NLRP3 inflammasome. Biomed Pharmacother 2017;86:32-40.

Hu Q. DHM inhibits NLRP3 inflammasome-dependent pyroptosis by activating the Nrf2 signaling pathway in vascular endothelial cells (Dissertation). Chongqing: Army Medcal University; 2017.

Hu Q, Zhang T, Yi L, et al. Dihydromyricetin inhibits NLRP3 inflammasome-dependent pyroptosis by activating the Nrf2 signaling pathway in vascular endothelial cells. Biofactors 2018;44:123-136.

Yan L. Baicalin-mediated inhibition of NLRP3 inflammasome activation in macrophages and the underlying action mechanism (Dissertation). Guangzhou: Jinan University;2018.

Zhao JF, Wang ZT, Yuan ZL, et al. Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice. Diab Vasc Dis Res 2020;17:1479164120977441.

Jiang Y, Du HJ, Liu X, et al. Artemisinin alleviates atherosclerotic lesion by reducing macrophage inflammation via regulation of AMPK/NF-κB/NLRP3 inflammasomes pathway. J Drug Target 2020;28:70-79.

He HB. The effect and mechanism of oridonin in inhibition of NLRP3 inflammasome activation and alleviation of NLRP3-driven diseases (Dissertation). Hefei: University of Science and Technology of China; 2018.

He HB, Jiang H, Chen Y, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun 2018;9:2550.

Jourdan T, Godlewski G, Cinar R, et al. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 2016;530:354-357.

Ma QX, Yang QQ, Chen JJ, et al. Salvianolic acid A ameliorates early-stage atherosclerosis development by inhibiting NLRP3 inflammasome activation in Zucker diabetic fatty rats. Molecules 2020;25:1089.

Nyandwi JB, Ko YS, Jin H, et al. Rosmarinic acid inhibits oxLDL-induced inflammasome activation under high-glucose conditions through downregulating the p38-FOXO1-TXNIP pathway. Biochem Pharmacol 2020;182:114246.

Zhang Y, Yang XQ, Qiu C, et al. Matrine suppresses AGE-induced HAEC injury by inhibiting ROS-mediated NRLP3 inflammasome activation. Eur J Pharmacol 2018;822:207-211.

Hu R, Wang MQ, Ni SH, et al. Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK/NF-κB/NLRP3 signaling pathway in AGEs-induced HUVECs. Eur J Pharmacol 2020;867:172797.

Wen JX. Molecular mechanism of tanshinone Ⅱ A anti-atherosclerosis based on inflammasome activation(Dissertation). Shijiazhuang: Hebei Agricultural University; 2014.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Guanxin Ⅴ Relieves Ventricular Remodeling by Inhibiting Inflammation: Implication from Virtual Screening, Systematic Pharmacology, Molecular Docking, and Experimental Validation

Anti-inflammatory Therapy Progress in Major Adverse Cardiac Events after PCI: Chinese and Western Medicine^*

Related Author

No data

Related Institution

Department of Cardiology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

Department of Nephrology, the Key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University)

School of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine

Graduate School of Beijing University of Chinese Medicine

Department of Cardiology,Dongzhimen Hospital, Beijing University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰